Ultomiris (ravulizumab-cwvz) is a monoclonal antibody that helps the body’s immune system by targeting and destroying certain cells, helping to protect healthy cells from damage.
Ultomiris is used to treat adults with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare genetic disorder in which defective red blood cells break down prematurely and leak hemoglobin into the blood. Ultomiris is also used to treat adults and children 1 month of age and older with a disease called atypical Hemolytic Uremic Syndrome (aHUS).
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
WHAT IT TREATS:
Hematologists or other prescribers specifically enrolled in the Ultomiris REMS program
Every 8 weeks, starting 2 weeks after an initial loading dose
Length of infusion:
Usually over about 2 hours in adults and up to 4 hours in children